Vitale, Martina
Orsi, Emanuela
Solini, Anna
Garofolo, Monia
Resi, Veronica
Bonora, Enzo
Fondelli, Cecilia
Trevisan, Roberto
Vedovato, Monica
Penno, Giuseppe
Pugliese, Giuseppe
Funding for this research was provided by:
Fondazione Diabete Ricerca (NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA)
Diabetes, Endocrinology and Metabolism Foundation (NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA)
Eli Lilly and Company (NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA)
Sigma-tau (NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA)
Boehringer Ingelheim (NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA)
Chiesi Farmaceutici (NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA)
Takeda Pharmaceutical Company (NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA)
Article History
Received: 13 November 2023
Accepted: 28 December 2023
First Online: 13 January 2024
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki. The research protocol was approved by the ethics committee of the coordinating centre (Sant’Andrea Hospital, Rome, Italy) on 25 September 2006 (number 43/2006) and subsequently by the ethics committee of each participating centre. Participants provided an informed consent.
: Not applicable.
: The RIACE Study Group.
: Baseline clinical features of study participants by history of ulcer/gangrene and/or amputation.
: Baseline clinical features of study participants by history of ulcer/gangrene/amputation and/or lower limb revascularization.
: Binary backward logistic regression analysis of the independent correlates of history of diabetic foot.
: MVi: lecture fees from MundiPharma and Novo Nordisk. EO: consultant fees from Eli Lilly and Novo Nordisk, and lecture fees from Astellas. AS: consultant fees from Axxam, Bayer, and Novo Nordisk, and lecture fees from Eli Lilly, Novo Nordisk, and Sanofi-Aventis. MG: consultant fees from Eli Lilly, and lecture fees from Eli Lilly, Merck Sharp & Dohme, and Novo Nordisk. VR: lecture fees from Astra-Zeneca, Eli Lilly, and Sanofi-Aventis. EB: consultant fees from Abbott, Bayer, Becton Dickinson, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, and Novo Nordisk. CF: lecture fees from Abbot, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck Sharp & Dohme, Mundipharma, and Theras Lifetech. RT: consultant fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi-Aventis, and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. MVe: lecture fees from Lifescan and Novo Nordisk. GPe: consultant fees from Bayer and Eli Lilly, and lecture fees from AstraZeneca, Boerhinger Ingelheim, Eli-Lilly, Merck Sharp & Dohme, Mundipharma, Novo Nordisk, and Takeda. GPu: consultant fees from Abbot, Bayer, and Novo Nordisk, and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Mundipharma, and Novo Nordisk.